About This Initiative

The incredible clinical success of immune checkpoint inhibitors (ICIs) has resulted in widespread use across many cancer types. The indications for use continue to expand at a rapid pace and the development of novel ICIs and combination therapies continue to be evaluated for multiple indications. Observations and reports of toxicities, sometimes severe, have been described in nearly every organ system. These immune-related adverse events (irAEs) manifest differently depending on the pathway targeted by the therapy (i.e., CTLA-4 or PD-1/PD-L1), and the emerging use of combination therapies has only increased the frequency of adverse events.

This initiative will explore ICIs, their mechanisms of action and adverse effects, current and expanding indications, and strategies for early recognition of irAEs as well as effective management and best practices for patient education and monitoring.